ReGen Factor's Covid Reset-1 trial - FDA consulting group appointed


December 18, 2020

Our mutual goal is to expedite the Emergency Use Authorization process (EUA) and Investigational New Drug (IND) for the ReGen Factor bFGF Covid Reset drug to fight the after effects of Covid 19.


To achieve this goal we are working with our appointed FDA consultants and the FDA to compile the existing documentation required for the Pre-IND meeting and assist in the Clinical Trial Plan in preparation for the EUA/IND application. This meeting will provide further instruction and clear direction to proceed with either the EUA COVID-19 path or Peptide Skin and Scalp IND path. After this meeting there will be enough information to decide which application path will be most beneficial.



December, 18 2020

We are excited to announce the appointment of a leading FDA consulting group headquartered in Phoenix, Arizona as our new FDA consulting team. This FDA consulting group will be assisted by our FDA lawyer and consultant, Heather Bustos from the Bustos Group in Florida, USA.

ReGen Factor goals:
1. Regen Factor Pty Ltd plans to seek permission to execute a clinical trial under section 564 of the Federal Food, Drug, and Cosmetic Act to use ReGen Factor’s bFGF as a preventive, protective and/or therapeutic approach for COVID-19 treatment. This pathway will facilitate to fast track ReGen Factor’s PepFactor Scalp product and FDA approval for our bio-identical bFGF to treat Hydrogenous Alopecia.
2. Commence trials by 30 January 2021 for the effect of PepFactor in the treatment of Androgenetic Alopecia. These trials will follow the exact protocols as FDA trials. This study will include 30 to 50 patients and will conclude on 17 April 2021. 3. Receive FDA approval for our bio-identical bFGF as a biologic in PepFactor for treating Androgenetic Alopecia in both men and women. This form of alopecia is the most common globally. New York April 25,2019 - GLOBE NEWSWIRE publication estimated the global market size for alopecia at USD 8.64 billion in 2018 with a market growth of CARG 5.1%. The Alopecia Market is expected to reach USD 12.99 billion by 2026.

ReGen Factor's Covid Reset-1 trial


First Posted December 15th, 2020

ReGen Factor Oral Supplement


Supplement in the fight against Covid



Sydney, Australia (January 8, 2021) – ReGen Factor, the makers of PepFactor and producers of cost effective, bio-identical rh bFGF(recombinant human Basic Fibroblast Growth Factor), today announced they have formulated a proprietary oral supplement that boost energy levels and the immune system against Covid-19. The new oral supplement’s main ingredients including bFGF is delivered to the intestine by bypassing the acidity of the stomach with ReGen Factor’s proprietary delivery technology.


Independent research has shown that bFGF protein administration markedly reduces mortality and the severity of lung injury. FGF functions as immunomodulatory factor by inducing the secretion of pro inflammatory factors in airway diseases. The role of bFGF in modulating the function of airway cells in remodeling, inflammation, and lung function could provide potential alternative options for patients that are unresponsive to current anti-inflammatory treatments being used in COVID-19.


RegenFactor plans to seek permission to executing a clinical trial under section 564 of the Federal Food, Drug, and Cosmetic Act to use ReGen Factor’s bFGF as a preventive, protective and/or therapeutic approach for COVID-19 treatment.


About ReGen Factor

ReGen Factor is the maker of PepFactor Skin and PepFactor Scalp treatments. ReGen Factor is known for producing the world’s only known cost effective and bio-identical bFGF. The company’s mission is to offer safe, fast, and effective treatments that offer never seen before results.

ReGen Factor appoints Barclay Pierce as Lead Managers

October 12th, 2020


We confirm that ReGen Factor  has engaged  Barclay Pearce Capital Pty Ltd to act as the Company’s Lead Manager and sponsoring broker in relation to the Company’s equity capital markets to organise and manage appropriate marketing programs aimed at promoting the Company to high net worth investors, retail clients and institutional investors where appropriate; and to assist in undertaking, arranging and managing capital raisings as a Lead Manager during the Term from investors.
Barclay Pearce Capital will  also manage all public relations, Investor relations and media publications (both print & digital) promote the company through broker roadshows (both deal and non deal) and to update the market with independent company research.

ReGen Factor announces appointment of Advisory Board


Posted on Oct 1st, 2020 

Australia, NSW, Nov 16, 2020 

ReGen Factor, a Sydney based cosmetics manufacturer, today announced the launch of its newly formed strategic committee of trusted advisors. This Advisory Board includes distinguished hair restoration and related physicians and industry leaders whose focus will be to shape and guide the strategy and go-to-market priorities of ReGen Factor, working closely with the leadership team. 

The Board will be chaired by Dr Hardik Soni.  "I am very pleased to have been asked to chair the Board of Advisors for ReGen Factor and support its strategic planning and execution in the marketplace,” said Dr. Soni.  “ReGen Factor offers the next generation of hair restoration services and this team has the expertise and experience to help guide it forward in the market.”

ReGen Factor Advisory Board members


Dr Hardik Soni

MD - University of Baltimore 


Dr Soni is the founder of FaceMedStore and Ethos Spa. Dr. Soni finished his undergraduate studies at Johns Hopkins University in Baltimore, MD. He is board certified in Emergency Medicine and currently works as an emergency room physician at Overlook Medical Center as well as serving as medical director of Ethos Spa, Skin and Laser Center in both the Summit and Englewood locations. He was recently chosen to the Advisory Medical Panel of Bella Magazine in NYC.



Dr Robert Dorin, DO

Diplomate of the American Board of Hair Restoration Surgery.

B.S. Stony Brook University.

DO New York College of Osteopathic Medicine, Traditional Rotating Internship. 

Residency, Good Samaritan Hospital Medical Centre, West Islip, New York.

Member of the International Society of Hair Restoration Surgery.


Diplomate ABHRS, Manhattan, New York.


Member of:

American Board of Restoration Surgery.

International Alliance of Hair Restoration Surgeons.

American Osteopathic Association.

American College of Osteopathic Family Physicians.

New York State Osteopathic Medical Society.

Dr Dorin as a Partner and Surgeon at True and Dorin and a leading hair transplant surgeon in Manhattan, New York.


Dr. Dorin graduated Cum Laude with a Bachelor of Science in Bio-Chemistry from Stony Brook University, Stony Brook, NY in December 1993. Following his graduation, Dr Dorin worked in the Pediatric Urology Department at Long Island Jewish Medical Center for 18 months as a researcher. Here Dr Dorin performed Northern Analysis on animal and human tissue searching for the expression of the Wilms Tumor gene.

Dr. Dorin pursued and received his doctorate at the New York College of Osteopathic Medicine in Old Westbury NY in May 1999.

In June of 2002 Dr Dorin completed a traditional rotating internship and his residency training at Good Samaritan Hospital Medical Center, West Islip N.Y.-Department of Family Medicine.


Dr Dorin was invited to become an associate of Dr. True's in February 2002. (Pending completion of Dr Dorin's residency). 

While an associate, Dr True served as Dr Dorin's mentor, as he imparted his vast knowledge and experience of hair restoration to Dr. Dorin. Two years later Dr Dorin became a partner with Dr True of the True and Dorin Medical Group, P.C. In 2013, Dr Dorin became the sole owner of True and Dorin Medical Group, P.C. He remains a top hair restoration surgeon in Manhattan and the greater NYC communities.

Dr Dorin is a Diplomate of the American Board of Hair Restoration Surgery, Certified (1/07). Dr Dorin is also board certified in Family Practice. He is a member of the: International Society of Hair Restoration Surgeons (ISHRS), Coalition of Independent Hair Restoration Physicians, International Alliance of Hair Restoration Surgeons (IAHRS), AOA, ACOFP, and New York State Osteopathic Medical Society.

Dr Ben Chan

Medical Director of Aesthetics and Skin Institute (formerly Cosmetic Institute of Australia)

Principal of Skintech Group of Cosmetic Clinics.

Principal of Dandenong Superclinic, Glen Superclinic and Box Hill Superclinics.

Medical director of Anatomy for Injectors online module.

Mole check Australia and

Hair Regrowth Clinic.

Fellow of:

Fellow Member of Cosmetic Physicians College of Australasia and Australasian College of Aesthetic Medicine.
Australasian College of Aesthetic Medicine.
Cosmetic Physician College of Australasia.


Dr Chan also specialises in providing cosmetic training to doctors, nurses, beauty therapists, dentists and those who want to get into aesthetic field. Author of Anatomy for Injectors online resource. He is a Fellow Member of Cosmetic Physicians College of Australasia and Australasian College of Aesthetic Medicine and member of Australasian College of Aesthetic Medicine and Cosmetic Physician College of Australasia.


Kimberly Vaughn



World Trichology Master Certificate


Managing Director of HPIHair Partners, Trichologist, and Hair Loss Specialist. Ms. Vaughn earned her MBA in California followed by her World Trichology Master certification after relocating to Nashville, TN.  Her 20 years of experience as a recognized World Trichologist and Hair Loss Specialist has given her a credible reputation as a trusted leader and educator in the hair loss industry. Her drive and passion span the aesthetic and healthcare aspects specializing in hair preservation, hair restoration, and hair replacement, addressing hair loss challenges for men and women. The ultimate success is for her clients and patients to regain their confidence, once again, and feel great about their appearance.

About ReGen Factor

Jan 1, 2021


ReGen Factor offers hair restoration and anti-aging skin treatment solutions to med-spa owners, medical practitioners, DOs, RNs, and aesthetic professionals globally. ReGen Factor operates in the multi-billion global anti-aging and hair restoration markets. ReGen Factor's offerings delivers “never seen before” results for anti-aging face and skin treatments in additional to unparalleled solutions for hair restoration with safe, fast, and effective treatments. ReGen Factor is the owner of PepFactor Skin and PepFactor Scalp cosmetic treatments globally and are headquartered in Sydney, Australia. 

"This is an important milestone for ReGen Factor," said Stephen Blignaut, CEO of ReGen Factor. "We thoughtfully curated this board to include hair transplant, general medicine, med-spa and marketing industry experts whose collective experience ensures ReGen Factor has the guidance it needs to navigate its way in the dynamic anti-aging and hair restoration markets.

About ReGen Factor:

ReGen Factor is a company delivering disruptive solutions in the anti-aging skin and hair restoration markets offering new age products; PepFactor Scalp and PepFactor skin treatments for fast and never seen before results.

For more information visit:

SOURCE ReGen Factor

CEO Blog: Timelines and Strategies

PepFactor Scalp Cosmetic trials commences.

Posted on Jan 1st, 2021

ReGen Factor commenced stag 1 clinical trials to prove the effectiveness of PepFactor Scalp for hair regrowth. The test will be conducted in accordance to stringent FDA regulations. This cosmetic trial is set to be completed by end April 2021. The double blind trials will be conducted in 4 separate sites. Three of the sites is situated in the USA and one site in Australia. The aim of this study is to prove the effectiveness of PepFactor Scalp for the treatment of Androgynous Alopecia in both men and women.


CEO:BLOG: ReGen Factor - Biologic medicine and growth factors for treatment of diseases and life extension.

December 12, 2020


We are at the forefront of a new revolution in medicine since Stanley Cohen and Rita Levi-Montalcini were jointly awarded the Noble Prize for medicine in 1986 for their discovery of growth factors.


Growth factors are important morphogenetic proteins that instruct cell behaviour and guide tissue repair and renewal.


Regenerative medicine, growth factors, stem cell therapies and RNA.

ReGen Factor can produce all fibroblast growth factors bio-identically and cost effectively. ReGen Factor can also produce 3d Stem cells, Exosomes, and RNA cost effectively.

ReGen Factor has also developed various delivery mechanisms for growth factors and 3d stem cells for inhalation. We plan to develop the further treatments in the future, after we have established PepFactor Skin and PepFactor Scalp.



CEO BLOG: ReGen Factor Physicians network. 


PepFactor – main ingredient bFGF

At present ReGen Factor is concentrating all efforts on expanding the market size for PepFactor Scalp for hair regrowth and PepFactor Skin for skin rejuvenation treatments with our proven formulations for Scalp and Skin treatments – over 10 000 treatments completed. These endeavours include growing our network of physicians that use PepFactor Skin and PepFactor Scalp in their clinics. We are on target to have 10 000 doctors globally by 2026 who use PepFactor Scalp for hair regeneration and PepFactor Skin for Anti Aging treatments. ​

CEO BLOG - Future ReGen Factor treatments


September 9, 2020


The Longevity Industry will be the Biggest and Most Complex Industry in Human History and The Longevity industry will dwarf all other industries in both size and market capitalization.


Regenerative medicine has the potential to heal or replace tissues and organs damaged by age, disease, or trauma, as well as to normalize congenital defects. Promising preclinical and clinical data to date support the possibility for treating both chronic diseases and acute insults, and for regenerative medicine to abet maladies occurring across a wide array of organ systems and contexts, including dermal wounds, cardiovascular diseases and traumas, treatments for certain types of cancer, and more (13). The current therapy of transplantation of intact organs and tissues to treat organ and tissue failures and loss suffers from limited donor supply and often severe immune complications, but these obstacles may potentially be bypassed through the use of regenerative medicine strategies.  - Engineering growth factors for regenerative medicine applications - Angelo S. Mao and David J. MooneyPNAS November 24, 2015



Future ReGen Factor products


July 10, 2020


ReGen Factor Ulcer Heal

ReGen Factor Diabetic Ulcer heal cream - Main ingredient – bFGF

Treatment – Hard to Heal wounds and Diabetic ulcers

ReGen Factor Ulcer heal

Already available for trials


In diabetic ulcers, FGF-2, also known as basic fibroblast growth factor, is related to wound healing (46). FGF-2 is thought to mediate angiogenesis during wound healing - [Frontiers In Bioscience, Landmark, 23, 310-317, January 1, 2018] - Growth factors in the pathogenesis of diabetic foot ulcers.


The global diabetic foot ulcer treatment market size was valued at USD 3.6 billion in 2017. It is anticipated to expand at a CAGR of 8.2% over the forecast period. Rising prevalence of diabetes and rapidly growing geriatric population worldwide are among the primary growth stimulants for DFU treatment market.

Future ReGen Factor products


ReGen Factor – ReGen Metabol Boost

July 10, 2020

Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism

Scientific Reports volume 8, Article number: 15973 (2018) 

We propose that BP3 may constitute a new therapeutic to reverse the pathology associated with metabolic syndrome that includes nonalcoholic fatty liver disease and type 2 diabetes mellitus.


Main ingredient – FGF bp3

ReGen Factor – ReGen Metabol Boost

Treatment – weight loss

Treatment – Type 2 Diabetes

Treatment – Non-alcoholic fatty liver disease.

Sep 07, 2020 (Heraldkeepers) -- Global Weight Loss and Weight Management Diet Market is valued at approximately USD 192 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 10.5% over the forecast period 2020-2027.Sep 7, 2020


Global Type 2 Diabetes Market Set to Almost Double to $58.7 Billion. The global type 2 diabetes market is set to almost double from $31.2 billion in 2015 to $58.7 billion by 2025, representing a compound annual growth rate of 6.5%, according to research and consulting firm GlobalData.

To the great surprise of cancer researchers, a protein they investigated for its possible role in cancer turned out to be a powerful regulator of metabolism. The Georgetown University-led study found that forced expression of this protein in a laboratory strain of obese mice showed a remarkable reduction of their fat mass despite a genetic predisposition to eat all the time.

The study, published in Scientific Reports, suggests that the protein FGFBP3 (BP3 for short) might offer novel therapy to reverse disorders associated with metabolic syndrome, such as type 2 diabetes and fatty liver disease.

Because BP3 is a natural protein and not an artificial drug, clinical trials of recombinant human BP3 could begin after a final round of preclinical studies, investigators say.

"We found that eight BP3 treatments over 18 days was enough to reduce the fat in obese mice by over a third," says the study's senior investigator, Anton Wellstein, MD, PhD, a professor of oncology and pharmacology at Georgetown Lombardi Comprehensive Cancer Center.

The treatments also reduced a number of obesity-related disorders in the mice, such as hyperglycemia -- excess blood sugar that is often linked to diabetes -- and eliminated the fat in their once fatty livers. Clinical as well as microscopic examination of the mice showed no side effects, researchers say.


Future ReGen Factor products

ReGen Factor Skin-Guard

March 20, 2020

FGF bp 1 – for treating skin cancers / preventing skin cancer cells from dividing.

Potential as a generic ingredient for all cosmetic skin creams and sunscreen products.

Main ingredient FGF bp 1 – we nee 6 months lead time to produce this drug.


Examination of wild-type skin grafted onto Fgfbp1 GFP-knock-in reporter hosts and bone marrow transplants from the GFP-reporter model into wild-type hosts revealed that circulating Fgfbp1-expressing cells migrate into healing wounds. We conclude that tissue-resident and circulating Fgfbp1-expressing cells modulate skin carcinogenesis and inflammation - The Role of Fibroblast Growth Factor-Binding Protein 1 in Skin Carcinogenesis and Inflammation. PMID: 28864076


Future ReGen Factor products


Stem Cell inhalation and RNA for anti-aging


March 12, 2020

3D Stem Cells

Stem cells can play a crucial role in delaying the aging process. Stem cells, in combination with anti-aging genes, can create a sophisticated shield, which can prevent the effects of aging. Increased wear and tear of the body's natural stem cells, increases cellular damage, and accelerate the natural process of aging. Stem cells, together with anti-aging genes such as Klotho, play a crucial role in delaying the aging process. ... Stem cells in conjugation with anti-aging genes probably receive and neutralize most of the devastating signalling effects which are known to cause premature aging

In 2018, the global anti-aging market was estimated to be worth about 50.2 billion U.S. dollars. The anti-aging market is estimated to see a compound annual growth rate (CAGR) of 5.7 percent between 2018 and 2023. Society drives people in every way to look beautiful.